NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA285: 785–795, 2001PubMed
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA285: 785–795, 2001PubMed)| false
MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK,
et al.
; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int69: 1945–1953, 2006PubMed
MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK, ; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int69: 1945–1953, 2006PubMed10.1038/sj.ki.5000414)| false
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL,
et al.
: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters. Kidney Int92: 26–36, 2017PubMed
DamasiewiczMJ, EbelingPR: Management of mineral and bone disorders in renal transplant recipients. Nephrology (Carlton)22[Suppl 2]: 65–69, 2017PubMed10.1111/nep.13028)| false
KanisJA, JohnellO, OdenA, JohanssonH, McCloskeyE: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int19: 385–397, 2008PubMed
KanisJA, JohnellO, OdenA, JohanssonH, McCloskeyE: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int19: 385–397, 2008PubMed10.1007/s00198-007-0543-5)| false
MillerPD: Bone disease in CKD: A focus on osteoporosis diagnosis and management. Am J Kidney Dis64: 290–304, 2014PubMed10.1053/j.ajkd.2013.12.018)| false
National Kidney Foundation. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-CKD-MBD-Guideline-English.pdf. Accessed XXX XX, xxxx
National Kidney Foundation. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-CKD-MBD-Guideline-English.pdf. Accessed XXX XX, xxxx)| false
JadoulM, AlbertJM, AkibaT, AkizawaT, ArabL, Bragg-GreshamJL,
et al.
: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int70: 1358–1366, 2006PubMed
JadoulM, AlbertJM, AkibaT, AkizawaT, ArabL, Bragg-GreshamJL, : Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int70: 1358–1366, 2006PubMed10.1038/sj.ki.5001754)| false
WestSL, JamalSA, LokCE: Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant27: 2384–2388, 2012PubMed
WestSL, JamalSA, LokCE: Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant27: 2384–2388, 2012PubMed10.1093/ndt/gfr620)| false
KlawanskyS, KomaroffE, CavanaughPF, MitchellDY, GordonMJ, ConnellyJE, RossSD: Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int14: 570–576, 2003
KlawanskyS, KomaroffE, CavanaughPF, MitchellDY, GordonMJ, ConnellyJE, RossSD: Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int14: 570–576, 200310.1007/s00198-003-1435-y)| false
NickolasTL, McMahonDJ, ShaneE: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol17: 3223–3232, 2006PubMed
NickolasTL, McMahonDJ, ShaneE: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol17: 3223–3232, 2006PubMed10.1681/ASN.2005111194)| false
CocoM, RushH: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis36: 1115–1121, 2000PubMed10.1053/ajkd.2000.19812)| false
IsakovaT, CravenTE, SciallaJJ, NickolasTL, SchnallA, BarzilayJ,
et al.
; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone78: 23–27, 2015PubMed
IsakovaT, CravenTE, SciallaJJ, NickolasTL, SchnallA, BarzilayJ, ; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone78: 23–27, 2015PubMed10.1016/j.bone.2015.04.037)| false
ArnesonTJ, LiS, LiuJ, KilpatrickRD, NewsomeBB, St PeterWL: Trends in hip fracture rates in US hemodialysis patients, 1993–2010. Am J Kidney Dis62: 747–754, 2013PubMed
ArnesonTJ, LiS, LiuJ, KilpatrickRD, NewsomeBB, St PeterWL: Trends in hip fracture rates in US hemodialysis patients, 1993–2010. Am J Kidney Dis62: 747–754, 2013PubMed10.1053/j.ajkd.2013.02.368)| false
NairSS, MitaniAA, GoldsteinBA, ChertowGM, LowenbergDW, WinkelmayerWC: Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol8: 1336–1342, 2013PubMed
NairSS, MitaniAA, GoldsteinBA, ChertowGM, LowenbergDW, WinkelmayerWC: Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol8: 1336–1342, 2013PubMed10.2215/CJN.10901012)| false
KimSM, LiuS, LongJ, Montez-RathME, LeonardMB, ChertowGM: Declining rates of hip fracture in end-stage renal disease: Analysis from the 2003–2011 nationwide inpatient sample. J Bone Miner Res32: 2297–2303, 2017PubMed
KimSM, LiuS, LongJ, Montez-RathME, LeonardMB, ChertowGM: Declining rates of hip fracture in end-stage renal disease: Analysis from the 2003–2011 nationwide inpatient sample. J Bone Miner Res32: 2297–2303, 2017PubMed10.1002/jbmr.3201)| false
WagnerJ, JhaveriKD, RosenL, SundayS, MathewAT, FishbaneS: Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant29: 146–151, 2014PubMed
KimSM, LongJ, Montez-RathM, LeonardM, ChertowGM: Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res31: 1803–1809, 2016PubMed
Mora PalmaFJ, EllisHA, CookDB, DewarJH, WardMK, WilkinsonR,
et al.
: Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med52: 332–348, 1983PubMed
Mora PalmaFJ, EllisHA, CookDB, DewarJH, WardMK, WilkinsonR, : Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med52: 332–348, 1983PubMed)| false
CarvalhoC, MagalhãesJ, NetoR, PereiraL, BrancoP, AdragãoT,
et al.
: Cortical bone analysis in a predialysis population: A comparison with a dialysis population. J Bone Miner Metab35: 513–521, 2017PubMed
CarvalhoC, MagalhãesJ, NetoR, PereiraL, BrancoP, AdragãoT, : Cortical bone analysis in a predialysis population: A comparison with a dialysis population. J Bone Miner Metab35: 513–521, 2017PubMed10.1007/s00774-016-0781-8)| false
HamdyNA, KanisJA, BenetonMN, BrownCB, JuttmannJR, JordansJG,
et al.
: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ310: 358–363, 1995PubMed
HamdyNA, KanisJA, BenetonMN, BrownCB, JuttmannJR, JordansJG, : Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ310: 358–363, 1995PubMed10.1136/bmj.310.6976.358)| false
MallucheHH, MawadHW, Monier-FaugereMC: Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res26: 1368–1376, 2011PubMed
MallucheHH, MawadHW, Monier-FaugereMC: Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res26: 1368–1376, 2011PubMed10.1002/jbmr.309)| false
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA,
et al.
: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis67: 559–566, 2016PubMed
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA, : Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis67: 559–566, 2016PubMed10.1053/j.ajkd.2015.06.023)| false
IimoriS, MoriY, AkitaW, KuyamaT, TakadaS, AsaiT,
et al.
: Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients: A single-center cohort study. Nephrol Dial Transplant27: 345–351, 2012PubMed
IimoriS, MoriY, AkitaW, KuyamaT, TakadaS, AsaiT, : Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients: A single-center cohort study. Nephrol Dial Transplant27: 345–351, 2012PubMed10.1093/ndt/gfr317)| false
YenchekRH, IxJH, ShlipakMG, BauerDC, RianonNJ, KritchevskySB,
et al.
; Health, Aging, and Body Composition Study: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol7: 1130–1136, 2012PubMed
YenchekRH, IxJH, ShlipakMG, BauerDC, RianonNJ, KritchevskySB, ; Health, Aging, and Body Composition Study: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol7: 1130–1136, 2012PubMed10.2215/CJN.12871211)| false
NaylorKL, GargAX, ZouG, LangsetmoL, LeslieWD, FraserLA,
et al.
: Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol10: 646–653, 2015PubMed
NaylorKL, GargAX, ZouG, LangsetmoL, LeslieWD, FraserLA, : Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol10: 646–653, 2015PubMed10.2215/CJN.06040614)| false
JamalSA, WestSL, NickolasTL: The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int25: 71–76, 2014PubMed
JamalSA, WestSL, NickolasTL: The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int25: 71–76, 2014PubMed10.1007/s00198-013-2524-1)| false
PrzedlackiJ, Buczyńska-ChylJ, KoźmińskiP, NiemczykE, WojtaszekE, GieglisE,
et al.
; Mazovia Fracture Study Group: The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: A two-year prospective multicenter cohort study. Osteoporos Int29: 1105–1115, 2018PubMed
PrzedlackiJ, Buczyńska-ChylJ, KoźmińskiP, NiemczykE, WojtaszekE, GieglisE, ; Mazovia Fracture Study Group: The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: A two-year prospective multicenter cohort study. Osteoporos Int29: 1105–1115, 2018PubMed10.1007/s00198-018-4406-z)| false
NickolasTL, SteinEM, DworakowskiE, NishiyamaKK, Komandah-KossehM, ZhangCA,
et al.
: Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res28: 1811–1820, 2013PubMed
NickolasTL, SteinEM, DworakowskiE, NishiyamaKK, Komandah-KossehM, ZhangCA, : Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res28: 1811–1820, 2013PubMed10.1002/jbmr.1916)| false
TrombettiA, StoermannC, ChevalleyT, Van RietbergenB, HerrmannFR, MartinPY,
et al.
: Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int24: 1721–1732, 2013PubMed
TrombettiA, StoermannC, ChevalleyT, Van RietbergenB, HerrmannFR, MartinPY, : Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int24: 1721–1732, 2013PubMed10.1007/s00198-012-2133-4)| false
CejkaD, PatschJM, WeberM, DiarraD, RiegerspergerM, KikicZ,
et al.
: Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol6: 2264–2271, 2011PubMed
JamalS, CheungAM, WestS, LokC: Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int23: 2805–2813, 2012PubMed
JamalS, CheungAM, WestS, LokC: Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int23: 2805–2813, 2012PubMed10.1007/s00198-012-1908-y)| false
PothuaudL, CarcellerP, HansD: Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture. Bone42: 775–787, 2008PubMed
PothuaudL, CarcellerP, HansD: Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture. Bone42: 775–787, 2008PubMed10.1016/j.bone.2007.11.018)| false
IkiM, TamakiJ, KadowakiE, SatoY, DongmeiN, WinzenriethR,
et al.
: Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: The Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res29: 399–407, 2014PubMed
IkiM, TamakiJ, KadowakiE, SatoY, DongmeiN, WinzenriethR, : Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: The Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res29: 399–407, 2014PubMed10.1002/jbmr.2048)| false
LuckmanM, HansD, CortezN, NishiyamaKK, AgarawalS, ZhangC,
et al.
: Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients. Clin J Am Soc Nephrol12: 644–652, 2017PubMed
LuckmanM, HansD, CortezN, NishiyamaKK, AgarawalS, ZhangC, : Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients. Clin J Am Soc Nephrol12: 644–652, 2017PubMed10.2215/CJN.09850916)| false
McCloskeyEV, OdénA, HarveyNC, LeslieWD, HansD, JohanssonH,
et al.
: A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res31: 940–948, 2016PubMed
McCloskeyEV, OdénA, HarveyNC, LeslieWD, HansD, JohanssonH, : A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res31: 940–948, 2016PubMed10.1002/jbmr.2734)| false
MuschitzC, KocijanR, HaschkaJ, PahrD, KaiderA, PietschmannP,
et al.
: TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone79: 259–266, 2015PubMed
MuschitzC, KocijanR, HaschkaJ, PahrD, KaiderA, PietschmannP, : TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone79: 259–266, 2015PubMed10.1016/j.bone.2015.06.007)| false
NaylorKL, PriorJ, GargAX, BergerC, LangsetmoL, AdachiJD,
et al.
: Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. Clin J Am Soc Nephrol11: 2032–2040, 2016PubMed
MallucheHH, Monier-FaugereM-C, BlomquistG, DavenportDL: Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporosis Int65: 235–134, 2017
MallucheHH, Monier-FaugereM-C, BlomquistG, DavenportDL: Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporosis Int65: 235–134, 2017)| false
BrauerCA, Coca-PerraillonM, CutlerDM, RosenAB: Incidence and mortality of hip fractures in the United States. JAMA302: 1573–1579, 2009PubMed10.1001/jama.2009.1462)| false
IsakovaT, NickolasTL, DenburgM, YarlagaddaS, WeinerDE, GutiérrezOM,
et al.
: KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis70: 737–751, 2017PubMed
IsakovaT, NickolasTL, DenburgM, YarlagaddaS, WeinerDE, GutiérrezOM, : KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis70: 737–751, 2017PubMed10.1053/j.ajkd.2017.07.019)| false
TitanSM, LaureatiP, SangY, ChangAR, EvansM, TrevisanM,
et al.
: Bisphosphonate utilization across the spectrum of eGFR. Arch Osteoporos15: 69–79, 2020PubMed
DamasiewiczMJ, NickolasTL: Bisphosphonate therapy in CKD: The current state of affairs. Curr Opin Nephrol Hypertens29: 221–226, 2020PubMed10.1097/MNH.0000000000000585)| false
MillerPD, RouxC, BoonenS, BartonIP, DunlapLE, BurgioDE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res20: 2105–2115, 2005PubMed
MillerPD, RouxC, BoonenS, BartonIP, DunlapLE, BurgioDE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res20: 2105–2115, 2005PubMed10.1359/JBMR.050817)| false
JamalSA, BauerDC, EnsrudKE, CauleyJA, HochbergM, IshaniA,
et al.
: Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res22: 503–508, 2007PubMed
JamalSA, BauerDC, EnsrudKE, CauleyJA, HochbergM, IshaniA, : Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res22: 503–508, 2007PubMed10.1359/jbmr.070112)| false
ShigematsuT, MuraokaR, SugimotoT, NishizawaY: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: Post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol18: 66–73, 2017PubMed
ShigematsuT, MuraokaR, SugimotoT, NishizawaY: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: Post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol18: 66–73, 2017PubMed10.1186/s12882-017-0478-9)| false
SugimotoT, InoueD, MaeharaM, OikawaI, ShigematsuT, NishizawaY: Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: A post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab37: 730–740, 2019PubMed
SugimotoT, InoueD, MaeharaM, OikawaI, ShigematsuT, NishizawaY: Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: A post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab37: 730–740, 2019PubMed10.1007/s00774-018-0977-1)| false
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis56: 57–68, 2010
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis56: 57–68, 201010.1053/j.ajkd.2009.12.039)| false
AliMS, ErnstM, RobinsonDE, CaskeyF, ArdenNK, Ben-ShlomoY,
et al.
: Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: An open cohort multivariable and propensity score analysis from Funen, Denmark. Arch Osteoporos15: 81–92, 2020PubMed
AliMS, ErnstM, RobinsonDE, CaskeyF, ArdenNK, Ben-ShlomoY, : Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: An open cohort multivariable and propensity score analysis from Funen, Denmark. Arch Osteoporos15: 81–92, 2020PubMed10.1007/s11657-020-00746-z)| false
AlarkawiD, AliMS, BliucD, PallaresN, TebeC, ElhusseinL,
et al.
: Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (Grade 3B-5D) chronic kidney disease: A population-based cohort study. J Bone Miner Res35: 894–900, 2020PubMed
CummingsSR, San MartinJ, McClungMR, SirisES, EastellR, ReidIR,
et al.
; FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med361: 756–765, 2009PubMed
CummingsSR, San MartinJ, McClungMR, SirisES, EastellR, ReidIR, ; FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med361: 756–765, 2009PubMed10.1056/NEJMoa0809493)| false
JamalSA, LjunggrenO, Stehman-BreenC, CummingsSR, McClungMR, GoemaereS,
et al.
: Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res26: 1829–1835, 2011PubMed
JamalSA, LjunggrenO, Stehman-BreenC, CummingsSR, McClungMR, GoemaereS, : Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res26: 1829–1835, 2011PubMed10.1002/jbmr.403)| false
BlockGA, BoneHG, FangL, LeeE, PadhiD: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res27: 1471–1479, 2012PubMed
BlockGA, BoneHG, FangL, LeeE, PadhiD: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res27: 1471–1479, 2012PubMed10.1002/jbmr.1613)| false
ChenCL, ChenNC, HsuCY, ChouKJ, LeePT, FangHC,
et al.
: An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab99: 2426–2432, 2014PubMed
ChenCL, ChenNC, HsuCY, ChouKJ, LeePT, FangHC, : An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab99: 2426–2432, 2014PubMed10.1210/jc.2014-1154)| false
NeerRM, ArnaudCD, ZanchettaJR, PrinceR, GaichGA, ReginsterJY,
et al.
: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med344: 1434–1441, 2001PubMed
NeerRM, ArnaudCD, ZanchettaJR, PrinceR, GaichGA, ReginsterJY, : Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med344: 1434–1441, 2001PubMed10.1056/NEJM200105103441904)| false
MillerPD, SchwartzEN, ChenP, MisurskiDA, KregeJH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int18: 59–68, 2007PubMed
MillerPD, SchwartzEN, ChenP, MisurskiDA, KregeJH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int18: 59–68, 2007PubMed10.1007/s00198-006-0189-8)| false
ImaiH, WatanabeM, FujitaT, WatanabeH, HaradaK, MoritoyoT; ANTCliPh (Academic Network for Trials in Clinical Pharmacology ) Trial 04 Study Group: Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: A pilot study. Int J Clin Pharmacol Ther52: 166–174, 2014PubMed
ImaiH, WatanabeM, FujitaT, WatanabeH, HaradaK, MoritoyoT; ANTCliPh (Academic Network for Trials in Clinical Pharmacology ) Trial 04 Study Group: Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: A pilot study. Int J Clin Pharmacol Ther52: 166–174, 2014PubMed10.5414/CP202001)| false
CejkaD, KodrasK, BaderT, HaasM: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study. Kidney Blood Press Res33: 221–226, 2010PubMed
CejkaD, KodrasK, BaderT, HaasM: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study. Kidney Blood Press Res33: 221–226, 2010PubMed10.1159/000316708)| false
SumidaK, UbaraY, HoshinoJ, MiseK, HayamiN, SuwabeT,
et al.
: Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int27: 1441–1450, 2016PubMed
BaharH, GallacherK, DownallJ, NelsonCA, ShomaliM, HattersleyG: Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int99: 489–499, 2016PubMed
BaharH, GallacherK, DownallJ, NelsonCA, ShomaliM, HattersleyG: Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int99: 489–499, 2016PubMed10.1007/s00223-016-0171-1)| false
MillerPD, HattersleyG, RiisBJ, WilliamsGC, LauE, RussoLA,
et al.
; ACTIVE Study Investigators: Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA316: 722–733, 2016PubMed
MillerPD, HattersleyG, RiisBJ, WilliamsGC, LauE, RussoLA, ; ACTIVE Study Investigators: Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA316: 722–733, 2016PubMed10.1001/jama.2016.11136)| false
MoreiraCA, FitzpatrickLA, WangY, ReckerRR: Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone97: 314–319, 2017PubMed
MoreiraCA, FitzpatrickLA, WangY, ReckerRR: Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone97: 314–319, 2017PubMed10.1016/j.bone.2016.11.004)| false
CosmanF, CrittendenDB, AdachiJD, BinkleyN, CzerwinskiE, FerrariS,
et al.
: Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med375: 1532–1543, 2016PubMed
McClungMR, GrauerA, BoonenS, BologneseMA, BrownJP, Diez-PerezA,
et al.
: Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med370: 412–420, 2014PubMed
McClungMR, GrauerA, BoonenS, BologneseMA, BrownJP, Diez-PerezA, : Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med370: 412–420, 2014PubMed10.1056/NEJMoa1305224)| false
SaagKG, PetersenJ, BrandiML, KaraplisAC, LorentzonM, ThomasT,
et al.
: Romosozumab or alendronate for fracture prevention in women with osteoporosis. n engl j med377: 1417–1427, 2017PubMed
SaagKG, PetersenJ, BrandiML, KaraplisAC, LorentzonM, ThomasT, : Romosozumab or alendronate for fracture prevention in women with osteoporosis. n engl j med377: 1417–1427, 2017PubMed10.1056/NEJMoa1708322)| false
LangdahlBL, LibanatiC, CrittendenDB, BologneseMA, BrownJP, DaizadehNS,
et al.
: Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet390: 1585–1594, 2017PubMed
